Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma.
NVO reports disappointing data from a phase III study on a novel obesity candidate, CagriSema. RHHBY buys rights to obesity candidate from Zealand Pharma.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results